Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia

Leukemia volume 16, pages 2096–2105 (2002)Cite this article

Abstract

Bendamustine is a novel cytostatic agent, with activity in non-Hodgkin's lymphomas including B-chronic lymphocytic leukemia (B-CLL). The knowledge about its mode of action, however, is still limited. Here, we investigated the in vitro ability of bendamustine to induce apoptosis on freshly isolated peripheral lymphocytes in B-CLL and analyze the potential underlying mechanisms of action for inducing apoptosis. In CLL cells taken from 37 previously treated and untreated CLL patients, we investigated the influence of bendamustine alone, and in combination with fludarabine, on the induction of apoptosis and changes of Bcl-2 and Bax expression on mRNA and protein level using the RNase protection assay or flow cytometry, respectively. Apoptotic cells were determined with flow cytometry using the fluorescent DNA-binding agent 7-ADD. Using bendamustine alone in concentrations from 1 μg/ml to 50 μg/ml, a dose- and time-dependent manner of cytotoxicity from 30.4% to 94.8% after 48 h could be observed. The LD50 for untreated and pretreated CLL cells was 7.3 or 4.4 μg/ml, respectively. The median apoptotic rate was similar in both groups. The combination of bendamustine with fludarabine led to a highly synergistic effect in inducing apoptosis, which was 150% higher than expected for bendamustine plus fludarabine. The level of the initial Bcl-2 and Bax protein and the m-RNA expression remained unchanged during the incubation with bendamustine. In conclusion, this study demonstrates for the first time the in vitro efficacy of bendamustine in inducing apoptosis in B-CLL cells alone and in combination with fludarabine.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC . A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  PubMed  Google Scholar 

  2. Foon KA, Rai KR, Gale RP . Chronic lymphocytic leukemia: new insights into biology and therapy Ann Intern Med 1990 113: 525–539

    Article  CAS  PubMed  Google Scholar 

  3. Rozman C, Montserrat E . Chronic lymphocytic leukemia N Engl J Med 1995 333: 1052–1057

    Article  CAS  PubMed  Google Scholar 

  4. Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K . Recent progress in chronic lymphocytic leukemia. International Workshop on Chronic Lymphocytic Leukemia Leukemia 1994 8: 1610–1614

    CAS  PubMed  Google Scholar 

  5. Wolowiec D, Benchaib M, Pernas P, Deviller P, Souchier C, Rimokh R, Felman P, Bryon PA, Ffrench M . Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue Leukemia 1995 9: 1382–1388

    CAS  PubMed  Google Scholar 

  6. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP, Zittoun R . Overexpression of cyclin D2 in chronic B-cell malignancies Blood 1995 85: 2870–2876

    CAS  PubMed  Google Scholar 

  7. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F . Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia Blood 1998 91: 4694–4700

    CAS  PubMed  Google Scholar 

  8. Reed JC . Bcl-2: prevention of apoptosis as a mechanism of drug resistance Hematol Oncol Clin North Am 1995 9: 451–473

    Article  CAS  PubMed  Google Scholar 

  9. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY . Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation Am J Pathol 1990 137: 225–232

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, Caligaris-Cappio F . Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells Blood 1992 79: 2981–2989

    CAS  PubMed  Google Scholar 

  11. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC . bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 1993 82: 1820–1828

    CAS  PubMed  Google Scholar 

  12. Pepper C, Bentley P, Hoy T . Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia Br J Haematol 1996 95: 513–517

    Article  CAS  PubMed  Google Scholar 

  13. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC . Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses Blood 1998 91: 3379–3389

    CAS  PubMed  Google Scholar 

  14. Gottardi D, De Leo AM, Alfarano A, Stacchini A, Circosta P, Gregoretti MG, Bergui L, Aragno M, Caligaris-Cappio F . Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations Br J Haematol 1997 99: 147–157

    Article  CAS  PubMed  Google Scholar 

  15. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A . Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death Exp Med 1996 183: 1957–1964

    Article  CAS  Google Scholar 

  16. Daniel PT . Dissecting the pathways to death Leukemia 2000 14: 2035–2044

    Article  CAS  PubMed  Google Scholar 

  17. Nicholson DW, Thornberry NA . Caspases: killer proteases Trends Biochem Sci 1997 22: 299–306

    Article  CAS  PubMed  Google Scholar 

  18. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT, Garrido C . Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies Leukemia 2000 14: 1833–1849

    Article  CAS  PubMed  Google Scholar 

  19. O'Gorman DM, Cotter TG . Molecular signals in anti-apoptotic survival pathways Leukemia 2001 15: 21–34

    Article  CAS  PubMed  Google Scholar 

  20. Bergmann L . Present status of purine analogs in the therapy of chronic lymphocytic leukemias Leukemia 1997 11: 29–34

    Google Scholar 

  21. Pott-Hoeck C, Hiddemann W . Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias Ann Oncol 1995 6: 421–433

    Article  CAS  PubMed  Google Scholar 

  22. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W . Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine Blood 1993 81: 143–150

    CAS  PubMed  Google Scholar 

  23. Schwaenen C, Karakas T, Bergmann L . Bendamustine in the treatment of low-grade non-Hodgkin's lymphomas Onkologie 2000 23: 318–324

    Google Scholar 

  24. Kath R, Blumenstengel K, Fricke HJ, Hoffken K . Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia J Cancer Res Clin Oncol 2001 127: 48–54

    Article  CAS  PubMed  Google Scholar 

  25. Heider A, Niederle N . Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas Anticancer Drugs 2001 12: 725–728

    Article  CAS  PubMed  Google Scholar 

  26. Balfour JA, Goa KL . Bendamustine Drugs 2001 61: 631–638

    Article  CAS  PubMed  Google Scholar 

  27. Schoffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, Kowalski R, Ganser A . Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours Ann Oncol 2000 11: 729–734

    Article  CAS  PubMed  Google Scholar 

  28. Borchmann P, Schnell R, Diehl V, Engert A . New drugs in the treatment of Hodgkin's disease Ann Oncol 1998 9: 103–108

    Article  Google Scholar 

  29. Hoffken K, Merkle K, Schonfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S . Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study J Cancer Res Clin Oncol 1998 124: 627–632

    Article  CAS  PubMed  Google Scholar 

  30. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S . Bendamustin hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines Anti-Cancer Drugs 1996 7: 415–421

    Article  CAS  PubMed  Google Scholar 

  31. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, Dalgleish AG, Gibson FM . The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques Blood 1996 87: 2244–2251

    CAS  PubMed  Google Scholar 

  32. Schmid I, Uittenbogaart CH, Keld B, Giorgi JV . A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry J Immunol Meth 1994 170: 145–157

    Article  CAS  Google Scholar 

  33. Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM . Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies Clin Cancer Res 1998 4: 445–453

    CAS  PubMed  Google Scholar 

  34. Friesen C, Herr I, Krammer PH, Debatin KM . Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells Nat Med 1996 2: 574–577

    Article  CAS  PubMed  Google Scholar 

  35. Chou TC, Talalay P . Quantitative analysis of dose–effect relationships: the combined effect of multiple drugs and enzyme inhibitors Adv Enzyme Regul 1984 22: 27–55

    Article  CAS  PubMed  Google Scholar 

  36. Chou TC, Talalay P . Application of the median-effect principle for the assessment of low-dose risk of carcinogens for the quantitation of synergism and antagonism of chemotherapeutics agents. In: Harrap KR, Conners TA (eds) New Avenues in Developmental Cancer Chemotherapy Academic Press: New York 1987 37–64

    Google Scholar 

  37. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P . Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia Br J Haematol 1999 107: 611–615

    Article  CAS  PubMed  Google Scholar 

  38. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA . In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues – correlation with clinical course Leukemia 1998 12: 1230–1235

    Article  CAS  PubMed  Google Scholar 

  39. Bellosillo B, Dalmau M, Colomer D, Gil J . Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells Blood 1997 89: 3378–3384

    CAS  PubMed  Google Scholar 

  40. Castejon R, Vargas JA, Briz M, Berrocal E, Romero Y, Gea-Banacloche JC, Fernandez MN, Durantez A . Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia Leukemia 1997 11: 1253–1257

    Article  CAS  PubMed  Google Scholar 

  41. Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M . Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia Blood 1998 91: 1742–1748

    CAS  PubMed  Google Scholar 

  42. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J . In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia Blood 1999 94: 2836–2843

    CAS  PubMed  Google Scholar 

  43. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M . Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression Int J Cancer 1996 69: 114–119

    Article  CAS  PubMed  Google Scholar 

  44. Molica S, Mannella A, Dattilo A, Levato D, Iuliano F, Peta A, Consarino C, Magro S . Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis Haematologica 1996 81: 302–309

    CAS  PubMed  Google Scholar 

  45. Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS, Neri A, Brugiatelli M . Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs Haematologica 1997 82: 16–20

    CAS  PubMed  Google Scholar 

  46. Kalil N, Cheson BD . Chronic lymphocytic leukemia Oncologist 1999 4: 352–369

    CAS  PubMed  Google Scholar 

  47. Klein A, Miera O, Bauer O, Golfier S, Schriever F . Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair Leukemia 2000 14: 40–46

    Article  CAS  PubMed  Google Scholar 

  48. Muller C, Calsou P, Salles B . The activity of the DNA-dependent protein kinase (DNA-PK) complex is determinant in the cellular response to nitrogen mustards Biochimie 2000 82: 25–28

    Article  CAS  PubMed  Google Scholar 

  49. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H . Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 1998 92: 1165–1171

    CAS  PubMed  Google Scholar 

  50. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Ichikawa A, Furukawa Y, Bai L, Kon K . In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis Leukemia 2000 14: 379–388

    Article  CAS  PubMed  Google Scholar 

  51. Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gillis E, Leveugle P, Deneys V, Ferrant A, Van den Berghe G . Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine Leukemia 1999 13: 918–925

    Article  CAS  PubMed  Google Scholar 

  52. Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, Scheinberg DA, Golde DW . Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 2000 14: 1577–1582

    Article  CAS  PubMed  Google Scholar 

  53. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E . In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine Haematologica 2001 86: 485–493

    CAS  PubMed  Google Scholar 

  54. Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B . German Chronic Lymphocytic Leukaemia Study Group. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group Br J Haematol 2001 114: 342–348

    Article  CAS  PubMed  Google Scholar 

  55. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M . Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 2001 19: 1414–1420

    Article  CAS  PubMed  Google Scholar 

  56. Adkins JC, Peters DH, Markham A . Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies Drugs 1997 53: 1005–1037

    CAS  PubMed  Google Scholar 

  57. Brock N . Oxazaphosphorine cytostatics: past–present–future. Seventh Cain Memorial Award lecture Cancer Res 1989 49: 1–7

    CAS  PubMed  Google Scholar 

  58. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, Horsman D, Berean K, Piro LD, Fugier-Vivier I, Liu YJ, Wang HG, Reed JC . Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes Blood 1997 89: 3817–3825

    CAS  PubMed  Google Scholar 

  59. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG . Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis Cancer Res 1993 53: 3976–3985

    CAS  PubMed  Google Scholar 

  60. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC . Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE Nature 1994 371: 346–347

    Article  CAS  PubMed  Google Scholar 

  61. Hübinger G, Müller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, Sigg I, Graf J, Bergmann L . CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299 Oncogene 2001 5: 590–598

    Article  Google Scholar 

  62. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu VL, Miller DK . Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 1995 376: 37–43

    Article  CAS  PubMed  Google Scholar 

  63. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR . Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood 1998 92: 3804–3816

    CAS  PubMed  Google Scholar 

  64. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ . Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes Blood 1997 90: 3673–3681

    CAS  PubMed  Google Scholar 

  65. King D, Pringle JH, Hutchinson M, Cohen GM . Processing/activation of caspases-3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells Leukemia 1998 12: 1553–1560

    Article  CAS  PubMed  Google Scholar 

  66. Zutter M, Hockenbery D, Silverman GA, Korsmeyer SJ . Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms Blood 1991 78: 1062–1068

    CAS  PubMed  Google Scholar 

  67. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, Caligaris-Cappio F . Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells Blood 1992 79: 2981–2989

    CAS  PubMed  Google Scholar 

  68. Korsmeyer SJ . Bcl-2 initiates a new category of oncogenes: regulators of cell death Blood 1992 80: 879–886

    CAS  PubMed  Google Scholar 

  69. Pepper C, Bentley P, Hoy T . Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia Br J Haematol 1996 95: 513–517

    Article  CAS  PubMed  Google Scholar 

  70. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW . Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance Oncogene 1996 12: 1055–1061

    CAS  PubMed  Google Scholar 

  71. Oltvai ZN, Milliman CL, Korsmeyer SJ . Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 1993 74: 609–619

    Article  CAS  PubMed  Google Scholar 

  72. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M . Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX J Immunol 1996 156: 2624–2630

    CAS  PubMed  Google Scholar 

  73. Begleiter A, Mowat M, Israels LG, Johnston JB . Chlorambucil in chronic lymphocytic leukemia: mechanism of action Leuk Lymphoma 1996 23: 187–201

    Article  CAS  PubMed  Google Scholar 

  74. Stoetzer OJ, Pogrebniak A, Scholz M, Pelka-Fleischer R, Gullis E, Darsow M, Nussler V, Wilmanns W . Drug-induced apoptosis in chronic lymphocytic leukemia Leukemia 1999 13: 1873–1880

    Article  CAS  PubMed  Google Scholar 

  75. Fadeel B, Orrenius S, Zhivotovsky B . The most unkindest cut of all: on the multiple roles of mammalian caspases Leukemia 2000 14: 1514–1525

    Article  CAS  PubMed  Google Scholar 

  76. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, Moss PA, Taylor AM . Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia Lancet 1999 353: 26–29

    Article  CAS  PubMed  Google Scholar 

  77. Prives C . Signaling to p53: breaking the MDM2-p53 circuit Cell 1998 95: 5–8

    Article  CAS  PubMed  Google Scholar 

  78. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M . Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia Cancer Res 1998 58: 4552–4557

    CAS  PubMed  Google Scholar 

  79. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Döhner K, Bentz M, Lichter P . Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 2000 343: 1910–1916

    Article  PubMed  Google Scholar 

  80. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S . p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood 1995 85: 1580–1589

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University of Ulm, Ulm, Germany

    C Schwänen, T Hecker, G Hübinger, M Wölfle & T Karakas

  2. Department of internal Medicine III, JW Goethe University, Frankfurt, Germany

    L Bergmann

  3. Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany

    W Rittgen

Authors
  1. C Schwänen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Hecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Hübinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Wölfle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Rittgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Karakas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwänen, C., Hecker, T., Hübinger, G. et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16, 2096–2105 (2002). https://doi.org/10.1038/sj.leu.2402651

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402651

Keywords

This article is cited by

Search

Advanced search

Quick links